Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs)
- 20 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 6038-6062
Abstract
Recent research has identified that adenosine A2A receptor (A2AR) antagonists are promising agents for cancer immunotherapy. However, their limited efficacy as monotherapies remains an unresolved challenge. A2AR/HDAC dual-targeting compounds have demonstrated more potent antitumor efficacy and warrant further investigation. To further improve the drug-like properties of such compounds in our previous work, a pharmacokinetics-driven structural optimization campaign was undertaken and led to the identification of compound 13t (IHCH-3185), which exhibited a markedly enhanced pharmacokinetic profile in mice. Furthermore, 13t retained potent target engagement (A2AR Ki = 7.6 nM, HDAC1 IC50 = 102.9 nM) and demonstrated broad-spectrum antiproliferative activity in vitro. Oral administration of 13t significantly inhibited CT26 and MC38 tumor growth in mice with tumor growth inhibition rates of 68.5% and 71.1%, respectively. This robust activity was attributed to a dual mechanism combining immune stimulation and direct antiproliferative effects. These results make 13t a promising cancer immunotherapy drug candidate.Keywords
Funding Information
- Shanghai Municipal People's Government (E315401030)
- Shanghai Municipal People's Government (E444104B02)
- ShanghaiTech University
- National Natural Science Foundation of China (22207075)
This publication has 48 references indexed in Scilit:
- Ifupinostat: First ApprovalDrugs, 2025
- The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategiesActa Pharmaceutica Sinica B, 2023
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Targeting histone deacetylases for cancer therapy: Trends and challengesActa Pharmaceutica Sinica B, 2023
- Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylasesChinese Chemical Letters, 2023
- Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activityActa Pharmaceutica Sinica B, 2020
- Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic CancerAngewandte Chemie International Edition, 2020
- Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics2018
- The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyCancer Immunology, Immunotherapy, 2017
- Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidinesBioorganic & Medicinal Chemistry Letters, 2009